Diapride MS1 vs Oxra S
Searching the Web
Diapride MS1 glimepiride metformin sustained release tablet composition
Searching the Web
Oxra S dapagliflozin saxagliptin tablet India composition
Reading File
Finding Sources
Finding Sources
Here is a detailed comparison of Diapride MS1 vs Oxra S:
Diapride MS1 vs Oxra S - Drug Comparison
| Feature | Diapride MS1 | Oxra S |
|---|---|---|
| Composition | Glimepiride 1 mg + Metformin SR 500 mg + Sitagliptin 50 mg | Dapagliflozin 10 mg + Sitagliptin 100 mg |
| Drug Classes | Sulfonylurea + Biguanide + DPP-4 inhibitor (triple combo) | SGLT2 inhibitor + DPP-4 inhibitor (dual combo) |
| Manufacturer | Micro Labs | Sun Pharma / generic |
| Metformin | Yes (SR 500 mg) | No |
| Insulin secretagogue | Yes (glimepiride - sulfonylurea) | No |
| Hypoglycemia risk | Higher (due to glimepiride) | Lower (SGLT2i + DPP4i have low intrinsic hypoglycemia risk) |
| Weight effect | Weight neutral to slight gain (glimepiride) | Weight loss (dapagliflozin promotes glycosuria) |
| CV/renal benefits | Limited (metformin has modest CV benefit) | Significant - dapagliflozin has proven cardioprotective and renoprotective effects (DECLARE-TIMI 58, DAPA-HF, DAPA-CKD trials) |
| Mechanism | Stimulates insulin release + reduces hepatic glucose + prolongs GLP-1 action | Urinary glucose excretion + prolongs GLP-1 action |
| Renal caution | Metformin CI if eGFR <30; glimepiride caution <45 | Dapagliflozin loses efficacy at low eGFR (<45); but DAPA-CKD shows benefit down to eGFR 25+ |
| Heart failure | Neutral/caution | Preferred - dapagliflozin approved for HFrEF/HFpEF |
| Urogenital infections | No | Increased genital mycotic infections (SGLT2i class effect) |
| DKA risk | Low | Low, but rare euglycemic DKA possible with dapagliflozin |
| Tablet count | Triple combination in one tablet | Dual combination |
When to Prefer Each
Diapride MS1 - better for:
- Patients needing aggressive glucose lowering with triple therapy
- Cost-sensitive patients (older generics, cheaper)
- When insulin secretagogue action is needed (e.g., postprandial spikes)
- HbA1c far from target requiring multiple mechanisms
Oxra S - better for:
- Patients with established cardiovascular disease or heart failure
- Chronic kidney disease (dapagliflozin has nephroprotective evidence)
- Patients who are overweight/obese (weight loss benefit)
- Those at high hypoglycemia risk (elderly, erratic meals)
- Patients where metformin is contraindicated (renal impairment)
Shared Component
Both contain sitagliptin (a DPP-4 inhibitor), though at different doses (50 mg in Diapride MS1 vs 100 mg in Oxra S).
Key Takeaway
Diapride MS1 is a conventional triple oral antidiabetic with strong glucose-lowering but higher hypoglycemia risk and no organ-protective advantages beyond metformin's modest CV benefit.
Oxra S is a modern combination offering cardiorenal protection beyond glucose control, with a favorable weight and hypoglycemia profile - making it the preferred choice in patients with comorbid CV disease, heart failure, or CKD, per current ADA Standards of Care guidelines which prioritize SGLT2 inhibitors in such patients regardless of baseline HbA1c.
When is the indication
Finding Sources
Finding Sources
Searching the Web
Diapride MS1 Oxra S indications approved uses India prescribing
Here is a full breakdown of when to use each drug - i.e., their indications:
Indications
Diapride MS1 (Glimepiride 1 mg + Metformin SR 500 mg + Sitagliptin 50 mg)
Primary Indication:
- Type 2 Diabetes Mellitus in adults
Specifically prescribed when:
- Blood sugar is not adequately controlled by dual therapy (e.g., metformin + one other agent) and a triple oral combination is needed
- Patient needs escalation of therapy without adding an injectable
- Predominantly glucose-lowering is the main goal (HbA1c reduction)
- No major cardiovascular or renal comorbidities requiring organ protection
- Cost is a concern (cheaper option vs newer agents)
NOT indicated in:
- Type 1 diabetes
- Diabetic ketoacidosis
- Renal impairment (eGFR <30 - metformin contraindicated; caution <45)
- Hepatic failure
- Pregnancy / lactation
- Patients undergoing iodinated contrast procedures (metformin)
Oxra S (Dapagliflozin 10 mg + Sitagliptin 100 mg)
Primary Indication:
- Type 2 Diabetes Mellitus in adults
Additionally approved / indicated for:
| Indication | Evidence |
|---|---|
| Heart Failure with reduced EF (HFrEF) | DAPA-HF trial - reduces CV death + worsening HF |
| Heart Failure with preserved EF (HFpEF) | DELIVER trial - reduces hospitalisation |
| Chronic Kidney Disease (CKD) eGFR 25-75 | DAPA-CKD trial - slows progression, reduces ESKD |
| Established ASCVD (atherosclerotic CV disease) | DECLARE-TIMI 58 - reduces HF hospitalisation |
Specifically prescribed when:
- T2DM + established heart disease or high CV risk
- T2DM + heart failure (with or without reduced EF)
- T2DM + CKD (eGFR 25-75, uACR elevated)
- T2DM where weight loss is desired alongside glucose control
- T2DM where hypoglycemia risk must be minimized (elderly, erratic meals)
- Metformin is not tolerated or contraindicated
NOT indicated in:
- Type 1 diabetes (off-label risk of DKA)
- eGFR <25 (loses glycemic efficacy; CKD indication may still apply per guidelines)
- Recurrent urinary/genital tract infections
- Patients prone to volume depletion / hypotension
Simple Decision Guide
T2DM patient needs oral intensification
|
├── Has CV disease / HF / CKD? ──► OXRA S (preferred)
|
├── Obese / weight-loss needed? ──► OXRA S (preferred)
|
├── Hypoglycemia-prone / elderly? ──► OXRA S (preferred)
|
└── None of above, needs triple
therapy, cost-sensitive? ──► DIAPRIDE MS1
Bottom line: Both are for T2DM, but Oxra S has extended indications beyond glucose control - it is the preferred agent when the patient has heart failure, CKD, or established cardiovascular disease, as per current ADA 2024 Standards of Care. Diapride MS1 is a pure glucose-lowering triple combination with no proven cardiorenal benefits beyond metformin.
This is a shared conversation. Sign in to Orris to start your own chat.